Skip to main content

and
  1. Article

    Open Access

    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

    Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumo...

    Stephen L. Chan, Martin Schuler in Journal of Experimental & Clinical Cancer … (2022)

  2. Article

    Open Access

    TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

    Despite the increasing interest in targeting stromal elements of the tumor microenvironment, we still face tremendous challenges in develo** adequate therapeutics to modify the tumor stromal landscape. A maj...

    Angelo L. Grauel, Beverly Nguyen, David Ruddy, Tyler Laszewski in Nature Communications (2020)

  3. Article

    Open Access

    Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features

    The original version of this Article contained an error in the author affiliations. The affiliation of Kevin P. White with Tempus Labs, Inc. Chicago, IL, USA was inadvertently omitted. This has now been correc...

    Jason J. Pitt, Markus Riester, Yonglan Zheng, Toshio F. Yoshimatsu in Nature Communications (2019)

  4. Article

    Open Access

    Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features

    Racial/ethnic disparities in breast cancer mortality continue to widen but genomic studies rarely interrogate breast cancer in diverse populations. Through genome, exome, and RNA sequencing, we examined the mo...

    Jason J. Pitt, Markus Riester, Yonglan Zheng, Toshio F. Yoshimatsu in Nature Communications (2018)

  5. No Access

    Article

    Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

    We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19 relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells ...

    Elena J. Orlando, **a Han, Catherine Tribouley, Patricia A. Wood in Nature Medicine (2018)

  6. Article

    Open Access

    PureCN: copy number calling and SNV classification using targeted short read sequencing

    Matched sequencing of both tumor and normal tissue is routinely used to classify variants of uncertain significance (VUS) into somatic vs. germline. However, assays used in molecular diagnostics focus on known...

    Markus Riester, Angad P. Singh, A. Rose Brannon in Source Code for Biology and Medicine (2016)

  7. No Access

    Protocol

    Meta-Analysis in Gene Expression Studies

    This chapter introduces methods to synthesize experimental results from independent high-throughput genomic experiments, with a focus on adaptation of traditional methods from systematic review of clinical tri...

    Levi Waldron, Markus Riester in Statistical Genomics (2016)

  8. Article

    Open Access

    DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors

    To date, there have been no reports characterizing the genome-wide somatic DNA chromosomal copy-number alteration landscape in metastatic urothelial carcinoma. We sought to characterize the DNA copy-number pro...

    Richard M Bambury, Ami S Bhatt, Markus Riester, Chandra Sekhar Pedamallu in BMC Cancer (2015)

  9. Article

    Open Access

    ESTs and EST-linked polymorphisms for genetic map** and phylogenetic reconstruction in the guppy, Poecilia reticulata

    The guppy, Poecilia reticulata, is a well-known model organism for studying inheritance and variation of male ornamental traits as well as adaptation to different river habitats. However, genomic resources for st...

    Christine Dreyer, Margarete Hoffmann, Christa Lanz, Eva-Maria Willing in BMC Genomics (2007)